Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Sotera Health (SHC), Insmed (INSM)

Tipranks - Tipranks - Thu Apr 2, 4:34AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sotera Health (SHC), Insmed (INSM) and Scholar Rock Holding (SRRK) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Sotera Health (SHC)

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Sotera Health, with a price target of $20.00. The company’s shares closed last Tuesday at $14.34.

According to TipRanks.com, Sergott is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.5% and a 33.8% success rate. Sergott covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Fortrea Holdings Inc., and Pacific Biosciences. ;'>

Currently, the analyst consensus on Sotera Health is a Strong Buy with an average price target of $22.20, implying a 64.6% upside from current levels. In a report issued on March 17, Piper Sandler also maintained a Buy rating on the stock with a $24.00 price target.

See today’s best-performing stocks on TipRanks >>

Insmed (INSM)

Barclays analyst Eliana Merle maintained a Buy rating on Insmed today and set a price target of $237.00. The company’s shares closed last Tuesday at $163.52.

According to TipRanks.com, Merle is a 3-star analyst with an average return of 3.1% and a 39.7% success rate. Merle covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Ultragenyx Pharmaceutical, and 4D Molecular Therapeutics. ;'>

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $211.61, representing a 37.5% upside. In a report issued on March 24, TipRanks – Google also upgraded the stock to Buy with a $159.00 price target.

Scholar Rock Holding (SRRK)

Barclays analyst Etzer Darout maintained a Buy rating on Scholar Rock Holding today and set a price target of $53.00. The company’s shares closed last Tuesday at $49.16.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 25.7% and a 53.8% success rate. Darout covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Protagonist Therapeutics, and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $58.10, representing a 21.9% upside. In a report issued on March 19, Cantor Fitzgerald also maintained a Buy rating on the stock.

Read More on SHC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).